Laser brain treatment links earlier use to longer survival in patients

A tiny opening in the skull. A laser probe guided through the brain by real-time MRI. For patients with recurrent, difficult-to-access or inoperable tumors, that is the route of a treatment now linked to longer survival when doctors destroy more of the tumor and intervene earlier. Researchers at Washington University School of Medicine in St. Louis reached that conclusion after analyzing outcomes for 787 patients.

The procedure, called laser interstitial thermal therapy, or LITT, uses a robotically controlled probe. Once it reaches the tumor, the laser emits heat that kills surrounding tumor cells. The analysis drew on a prospective multicenter study that followed patients for up to five years after treatment at sites across the U.S.; the work was led by WashU Medicine at Siteman Cancer Center and 24 other locations.

For newly diagnosed glioblastoma, the result was stark: patients who had at least 91% of their tumor cleared survived 2.1 years from diagnosis. The researchers compared that outcome with approximately 1.5 years for standard open surgical resection, while noting that the laser approach is being considered particularly for tumors that are difficult or impossible to remove through open surgery.

The timing signal appeared in another group. For brain metastases after prior radiation therapy—cancers that have spread to the brain from elsewhere—the data favored treating tumors while they were still small, rather than waiting through several imaging cycles to confirm growth. That challenges watchful waiting for this specific situation, according to the analysis.

And so, concretely? Patients may face a less disruptive procedure and a more targeted treatment decision. The laser operation requires only a single-stitch incision a few millimeters wide, and the average hospital stay was 32 hours. Most patients avoided intensive care and readmission, and the procedure reduced the need for antiseizure medication compared with before surgery. The findings are an analysis of patient outcomes, but they give physicians two usable markers—tumor clearance and treatment timing—for deciding who may benefit most.